Applications of magnetic resonance in model systems: Cancer therapeutics

Neoplasia

Volumn 2, Issue 1-2, 2000, Pages 152-165

  Evelhoch, Jeffrey L ^a,j   Gillies, Robert J ^b   Karczmar, Gregory S ^c   Koutcher, Jason A ^d   Maxwell, Ross J ^e   Nalcioglu, Orhan ^f   Raghunand, Natarajan ^b   Ronen, Sabrina M ^g   Ross, Brian D ^h   Swartz, Harold M ⁱ  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ DARTMOUTH MEDICAL SCHOOL   (United States)

^j HARPER UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

Metabolism; Neoplasms; Nuclear magnetic resonance; Pathophysiology; Therapy

Indexed keywords

3 AMINOPROPANEPHOSPHINIC ACID; 6 AMINONICOTINAMIDE; 6 METHYLTHIOINOSINE; BICARBONATE; CERAMIDE; COMBRETASTATIN; CYCLOPHOSPHAMIDE; DEOXYGLUCOSE; FLUORINE; FLUOROURACIL; GADOLINIUM PENTETATE; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 1ALPHA; LONIDAMINE; MITOFLAXONE; MITOMYCIN C; OXYGEN; PACLITAXEL; PHOSPHATE; PHOSPHORUS 31; PHOSPHORYLCHOLINE; SPARFOSIC ACID; SPHINGOMYELIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; ELECTRON SPIN RESONANCE; GENE EXPRESSION; GENE THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PH; PRIORITY JOURNAL; REVIEW; TRANSGENE;

EID: 0034047595     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900078     Document Type: Review

References (116)

1. Gillies RJ, Bhujwalla ZM, Evelhoch JL, Garwood M, Neeman M, Robinson SP, Sotak CH, and van der Sanden B (2000). Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2, 139-152.
2. Kerr JF, Wyllie AH, and Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239-257.
3. Miller LJ, and Marx J (1998). Apoptosis. Science 281, 1301.
4. Hickman JA (1992). Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11, 121-139.
5. Pilatus U, Shim H, Artemov D, Davis D, van Zijl PC, and Glickson JD (1997). Intracellular volume and apparent diffusion constants of perfused cancer cell cultures, as measured by NMR. Magn Reson Med 37, 825-832.
6. 1H NMR spectroscopy. NMR Biomed 11, 11-18.
7. Blankenberg FG, Storrs RW, Naumovski L, Goralski T, and Spielman D (1996). Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 87, 1951-1956.
8. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med 5, 1323-1327.
9. Al-Saffar NM, Clarke PA, DiStefano F, Leach MO, and Ronen SM (1999). Detection of Metabolic Changes Associated with Fas-and Chemotherapy-Induced Apoptosis Using MRS. In ISMRM 7th Scientific Meeting. ISMRM, Philadelphia, PA.
10. Anthony ML, Zhao M, and Brindle KM (1999). Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 274, 19686-19692.
11. 31P NMR characterization of cellular metabolism during dexamethasone induced apoptosis in human leukemic cell lines. J Cell Physiol 158, 180-186.
12. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, Titley J, Cunningham DC, Griffiths JR, Leach MO, and Clarke PA (1999). Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 80, 1035-1041.
13. 31P MRS. Magn Reson Med 40, 411-420.
14. Bogin L, Papa MZ, Polak-Charcon S, and Degani H (1998). TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim Biophys Acta 1392, 217-232.
15. Nunn AV, Barnard ML, Bhakoo K, Murray J, Chilvers EJ, and Bell JD (1996). Characterisation of secondary metabolites associated with neutrophil apoptosis. FEBS Lett 392, 295-298.
16. 31P MRS and Immunohistochemistry. In ISMRM 3rd Scientific Meeting. ISMRM, Nice, France.
17. Boddie AW, Jr., Constantinou A, Williams C, and Reed A (1998). Nitrogen mustard upregulates Bcl-2 and GSH and increases NTP and PCr in HT-29 colon cancer cells. Br J Cancer 77, 1395-1404.
18. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, and Dowsett M (1997). Preoperative chemotherapy induces apoptosis in early breast cancer [letter]. Lancet 349, 849.
19. Stejskal EO, and Tanner JE (1965). Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42, 288-292.
20. Cooper RL, Chang DB, Young AC, Martin CJ, and Ancker-Johnson D (1974). Restricted diffusion in biophysical systems. Experiment. Biophys J 14, 161-177.
21. Latour LL, Svoboda K, Mitra PP, and Sotak CH (1994). Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci USA 91, 1229-1233.
22. Peterson HI, Appelgren L, Kjartansson I, and Selander D (1976). Vascular and extravascular spaces in a transplantable rat tumour after local X-ray irradiation. Zeitschrift fur Krebsforschung und Klinische Onkologie - Cancer Research and Clinical Oncology 87, 17-25.
23. Braunschweiger PG (1988). Effect of cyclophosphamide on the pathophysiology of RIF-1 solid tumors. Cancer Res 48, 4206-4210.
24. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, and Laval-Jeantet M (1986). MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161, 401-407.
25. Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM, Dauser R, Pipe JG, and Betley AT (1995). In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres [published erratum appears in AJNR Am J Neuroradiol 16 (6), 1384:1995 Jun-Jul]. AJNR Am J Neuroradiol 16, 361-371.
26. Englander SA, Ulug AM, Brem R, Glickson JD, and van Zijl PC (1997). Diffusion imaging of human breast. NMR Biomed 10, 348-352.
27. Namimoto T, Yamashita Y, Sumi S, Tang Y, and Takahashi M (1997). Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 204, 739-744.
28. Yamashita Y, Namimoto T, Mitsuzaki K, Urata J, Tsuchigame T, Takahashi M, and Ogawa M (1998). Mucin-producing tumor of the pancreas: diagnostic value of diffusion-weighted echo-planar MR imaging. Radiology 208, 605-609.
29. Namimoto T, Yamashita Y, Mitsuzaki K, Nakayama Y, Tang Y, and Takahashi M (1999). Measurement of the apparent diffusion coefficient in diffuse renal disease by diffusion-weighted echo-planar MR imaging. J Magn Reson Imaging 9, 832-837.
30. 1H NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73, 61-64.
31. Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3, 1457-1466.
32. 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 58, 3791-3799.
33. Poptani H, Puumalainen AM, Grohn OH, Loimas S, Kainulainen R, Yla-Herttuala S, and Kauppinen RA (1998). Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5, 101-109.
34. Galons J-P, Altbach MI, Taylor CW, Payne-Murrietta G, and Gillies RJ (1999). Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1, 113-117.
35. 1H NMR spectroscopy in vivo. Magma 8, 20-26.
36. He Z (1999). Tumor therapeutic response detected by nuclear magnetic resonance diffusion measurement. PhD Dissertation, Wayne State University.
37. Corbett TH, and Valeriote FA (1987). Rodent Models in Experimental Chemotherapy. In Rodent Tumor Models in Experimental Cancer Therapy. RF Kallman (Ed). Pergamon Press, New York. pp. 233-252.
38. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, and Schild HH (1999). Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211, 101-110.
39. Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, Kopans DB, and Weisskoff RM (1997). Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205, 837-842.
40. Mayr NA, Yuh WT, Zheng J, Ehrhardt JC, Magnotta VA, Sorosky JI, Pelsang RE, Oberley LW, and Hussey DH (1998). Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 170, 177-182.
41. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schonberg SO, Vaupel P, and van Kaick G (1998). Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4, 2305-2312.
42. Schwickert HC, Stiskal M, Roberts TP, van Dijke CF, Mann J, Muhler A, Shames DM, Demsar F, Disston A, and Brasch RC (1996). Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 198, 893-898.
43. Cohen FM, Kuwatsuru R, Shames DM, Neuder M, Mann JS, Vexler V, Rosenau W, and Brasch RC (1994). Contrast-enhanced magnetic resonance imaging estimation of altered capillary permeability in experimental mammary carcinomas after X-irradiation. Invest Radiol 29, 970-977.
44. Su MY, Wang Z, and Nalcioglu O (1999). Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. J Magn Reson Imaging 9, 128-137.
45. Hellman S (1993). Principles of Chemotherapy. In Cancer: Principles and Practice of Oncology. VT DeVita, S Hellman, and SA Rosenberg (Eds). JB Lippincott Co., Philadelphia, PA. p. 255.
46. 31P NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro. J Biol Chem 271, 4113-4119.
47. Street JC, Alfieri AA, and Koutcher JA (1997). Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res 57, 3956-3962.
48. 31P NMR and tumor growth delay studies. Magn Reson Med 36, 887-892.
49. Koutcher JA, Alfieri AA, Stolfi RL, Devitt ML, Colofiore JR, Nord LD, and Martin DS (1993). Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res 53, 3518-3523.
50. Martin DS, Kligerman MM, and Fugman RA (1958). Radiotherapy and adjuvant combination chemotherapy (6 aminonicotinamide and 6-mertcaptopurine). Cancer Res 18, 893-896.
51. Varnes ME (1988). Inhibition of pentose cycle of A549 cells by 6-aminonicotinamide: consequences for aerobic and hypoxic radiation response and for radiosensitizer action. NCI Monogr 199-203.
52. Budihardjo, II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, and Kaufmann SH (1998). 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 4, 117-130.
53. Berger NA, Catino DM, and Vietti TJ (1982). Synergistic antileukemic effect of 6-aminonicotinamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on L1210 cells in vitro and in vivo. Cancer Res 42, 4382-4386.
54. 31P magnetic resonance spectroscopic study. Biochem Biophys Res Commun 164, 947-953.
55. Moyer JD, and Handschumacher RE (1979). Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Cancer Res 39, 3089-3094.
56. Warnick CT, and Paterson AR (1973). Effect of methylthioinosine on nucleotide concentrations in L5178Y cells. Cancer Res 33, 1711-1715.
57. Stolfi RL, Stolfi LM, Sawyer RC, and Martin DS (1988). Chemotherapeutic evaluation using clinical criteria in spontaneous, autochthonous murine breast tumors. J Natl Cancer Inst 80, 52-55.
58. 13C nuclear magnetic resonance studies. Cancer Res 55, 2814-2821.
59. Ben-Yoseph O, Lyons JC, Song CW, and Ross BD (1998). Mechanism of action of Ionidamine in the 9 L brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol 36, 149-157.
60. 31P magnetic resonance spectroscopy. Cancer Res 52, 71-76.
61. 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res 51, 1638-1644.
62. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, and Cohen JS (1990). Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 50, 544-551.
63. 13C NMR spectroscopic study of wild type and multidrug-resistant Ehrlich ascites tumor cells. Oncol Res 5, 119-126.
64. Warburg O (1956). On the origin of cancer cells. Science 123, 309-314.
65. Wike-Hooley JL, Haveman J, and Reinhold HS (1984). The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2, 343-366.
66. 31P MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267, C195-C203.
67. 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer 72, 905-911.
68. Roos A (1978). Weak acids, weak bases and intracellular pH. Respir Physiol 33, 27-30.
69. 31P magnetic resonance spectroscopy. Biochem Pharmacol 57, 309-312.
70. Tannock IF, and Rotin D (1989). Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49, 4373-4384.
71. Raghunand N, Martinez-Zaguilan R, Wright SH, and Gillies RJ (1999). pH and drug resistance: II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 57, 1047-1058.
72. van Bommel EF, Bouvy ND, So KL, Vincent HH, Zietse R, Bruining HA, and Weimar W (1995). High-risk surgical acute renal failure treated by continuous arteriovenous hemodiafiltration: metabolic control and outcome in sixty patients. Nephron 70, 185-192.
73. Applegate E (1999). Effective nutritional ergogenic aids. Int J Sport Nutr 9, 229-239.
74. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, and Gillies RJ (1999). Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80, 1005-1011.
75. Rentsch KM, Horber DH, Schwendener RA, Wunderli-Allenspach H, and Hanseler E (1997). Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer 75, 986-992.
76. Moulder JE, and Rockwell S (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5, 313-341.
77. Thomlinson RH, and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
78. Hockel M, Schlenger K, Mitze M, Schaffer U, and Vaupel P (1996). Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6, 3-9.
79. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, and Hill RP (1998). Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48, 149-156.
80. Sotak CH, Hees S HH, Hung MH, Krespan CG, and Raynolds S (1993). A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med 29 (2), 188-195.
81. 19F NMR indicator of tumor oxygenation. NMR Biomed 9, 125-134.
82. Swartz HM, and Clarkson RB (1998). The measurement of oxygen in vivo using EPR techniques. Phys Med Biol 43, 1957-1975.
83. Kallman RF (1988). Reoxygenation and repopulation in irradiated tumors. Front Radiat Ther Oncol 22, 30-49.
84. Hall EJ (1988). In Radiobiology for the Radiologist. J.B. Lippincott, Philadelphia, PA. p. 154.
85. 2 measurements by electron paramagnetic resonance oximetry. Radiat Res 150, 549-556.
86. Smirnov AI, Norby SW, Clarkson RB, Walczak T, and Swartz HM (1993). Simultaneous multi-site EPR spectroscopy in vivo. Magn Reson Med 30, 213-220.
87. Swartz HM, and Halpern H (1998). EPR Studies of Living Animals and Related Model Systems (In Vivo EPR). In Spin Labeling: The Next Millenium. LJ Berliner (Ed). Plenum Publishing, New York, NY. pp. 367-404.
88. Robinson SP, Howe FA, and Griffiths JR (1995). Non-invasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 33, 855-859.
89. 2* and resonance frequency-weighted magnetic resonance images of rodent tumours. NMR Biomed 7, 3-11.
90. Griffiths JR, Taylor NJ, Howe FA, Saunders MI, Robinson SP, Hoskin PJ, Powell ME, Thoumine M, Caine LA, and Baddeley H (1997). The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys 39, 697-701.
91. Al-Hallaq HA, Zamora M, River JN, and Karczmar GS (1999). MR Correctly Predicts the Relative Effect of Two Tumor-Oxygenating Agents on Hypoxic Fraction in Rodent BA1112 Tumors. In ISMRM 7th Scientific Meeting. ISMRM, Philadelphia, Pennsylvania, USA.
92. Al-Hallaq HA, River JN, Zamora M, Oikawa H, and Karczmar GS (1998). Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 41, 151-159.
93. Dunn JF, and Swartz HM (1997). Blood oxygenation. Heterogeneity of hypoxic tissues monitored using bold MR imaging. Adv Exp Med Biol 428, 645-650.
94. Vexler VS, de Crespigny AJ, Wendland MF, Kuwatsuru R, Muhler A, Brasch RC, and Moseley ME (1993). MR imaging of blood oxygenation-dependent changes in focal renal ischemia and transplanted liver tumor in rat. J Magn Reson Imaging 3, 483-490.
95. Moolten FL (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46, 5276-5281.
96. Hamstra DA, Rice DJ, Fahmy S, Ross BD, and Rehemtulla A (1999). Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 10, 1993-2003.
97. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy S, Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Tjuvajev J, and Blasberg R (2000). Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2, 118-138.
98. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, and Ross BD (1999). Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 96, 9821-9826.
99. Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, and Breakefield XO (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 6, 1543-1552.
100. Weissleder R, Simonova M, Bogdanova A, Bredow S, Enochs WS, and Bogdanov A, Jr. (1997). MR imaging and scintigraphy of gene expression through melanin induction. Radiology 204, 425-429.
101. Moore A, Basilion JP, Chiocca EA, and Weissleder R (1998). Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta 1402, 239-249.
102. Izquierdo M, Cortes M, de Felipe P, Martin V, Diez-Guerra J, Talavera A, and Perez-Higueras A (1995). Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 2, 66-69.
103. Ross BD, Kim B, and Davidson BL (1995). Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1, 651-657.
104. Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, and Davidson BL (1998). Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther 5, 740-746.
105. Hamstra DA, Rice DJ, Pu A, Oyedijo D, Ross BD, and Rehemtulla A (1999). Combined radiotherapy and enzyme/prodrug therapy for head and neck cancer in an orthotopic animal model. Radiat Res 152, 499-507.
106. Namba H, Tagawa M, Iwadate Y, Kimura M, Sueyoshi K, and Sakiyama S (1998). Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum Gene Ther 9, 5-11.
107. 31P magnetic resonance spectroscopy. Br J Cancer Suppl 27, S232-235.
108. Shine N, Palladino MA, Jr., Patton JS, Deisseroth A, Karczmar GS, Matson GB, and Weiner MW (1989). Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study. Cancer Res 49, 2123-2127.
109. 31P nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 a on the bioenergetics of RIF-1 tumors. Cancer Res 49, 6379-6382.
110. Evelhoch JL, Bissery MC, Chabot GG, Simpson NE, McCoy CL, Heilbrun LK, and Corbett TH (1988). Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 48, 4749-4755.
111. Breidahl T, Nielsen FU, Maxwell RJ, Stodkilde-Jorgensen H, and Horsman MR (1999). Evaluating The Anti-Tumour Activity of New Vascular-Damaging Agents Using Magnetic Resonance Spectroscopy. In ISMRM 7th Scientific Meeting. ISMRM, Philadelphia, PA.
112. Galbraith SM, Taylor NJ, Stirling JJ, Rustin G, and Baddeley H (1999). Dynamic Contrast-Enhanced MRI to Monitor Perfusion and Permeability Changes in Human Tumours During Treatment by the Vascular Targeting Agent DMXAA. In ISMRM 7th Scientific Meeting. ISMRM, PA, Philadelphia.
113. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, and Brindle KM (1998). Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77, 1761-1767.
114. 1H MRI. Int J Radiat Oncol Biol Phys 42, 891-894.
115. Abramovitch R, Frenkiel D, and Neeman M (1998). Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 39, 813-824.
116. 3-targeted magnetic resonance imaging. Nat Med 4, 623-626.